NCT03506854View on ClinicalTrials.gov

Study of ISIS 681257 in Patients With Renal Impairment Compared to Healthy Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

March 20, 2018

Primary Completion Date

October 11, 2018

Study Completion Date

October 11, 2018

Conditions
Renal Impairment
Interventions
DRUG

ISIS 681257

Xmg dose administered as a subcutaneous injection

Trial Locations (3)

32809

Clinical Site, Orlando

37920

Clinical Site, Knoxville

H7V4B3

Clinical Site, Québec

Sponsors

Lead Sponsor

Akcea Therapeutics
All Listed Sponsors
collaborator

Ionis Pharmaceuticals, Inc.

INDUSTRY

lead

Akcea Therapeutics

INDUSTRY